This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MenAfriVac | |
|---|---|
| Name | MenAfriVac |
| Type | conjugate vaccine |
| Target | Neisseria meningitidis serogroup A |
| Administered | intramuscular |
| Developer | PATH; Serum Institute of India |
| First licensed | 2010 |
| Routes of administration | intramuscular injection |
MenAfriVac is a conjugate vaccine developed to prevent epidemics of Neisseria meningitidis serogroup A across the Meningitis Belt of Sub-Saharan Africa. Initiated through collaborations involving World Health Organization, Bill & Melinda Gates Foundation, and PATH, the vaccine aimed to interrupt transmission, induce herd immunity, and reduce seasonal outbreaks associated with high morbidity and mortality. Clinical development, mass campaigns, and post-introduction surveillance engaged multiple partners including the Serum Institute of India, national ministries of health, and international public health agencies.
The public health crisis addressed by the vaccine arose from recurrent meningococcal meningitis epidemics across the African Great Lakes region, the Sahel, and countries such as Mali, Niger, Chad, Nigeria, and Burkina Faso. Historical epidemic waves drew attention from organizations like the World Health Organization, United Nations Children's Fund, and Médecins Sans Frontières. Outbreak responses prior to the conjugate vaccine often relied on polysaccharide vaccines produced by manufacturers such as GlaxoSmithKline and Sanofi Pasteur, which conferred limited duration of protection and poor impact on carriage, as documented in reports by Centers for Disease Control and Prevention and national public health institutes including Institut Pasteur.
The vaccine was developed through public–private partnerships involving PATH, the Bill & Melinda Gates Foundation, and the Serum Institute of India Private Limited. MenAfriVac is a conjugate vaccine combining a polysaccharide from Neisseria meningitidis serogroup A with a carrier protein, a strategy informed by immunology research from institutions such as Imperial College London, Oxford Vaccine Group, and Johns Hopkins Bloomberg School of Public Health. The conjugation approach built on earlier work with conjugate vaccines for Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis serogroup C implemented by companies like Wyeth and Pfizer. Regulatory review involved agencies including the World Health Organization prequalification program and national regulatory authorities in India and various African countries.
Phase I, II, and III trials were conducted in populations across India, The Gambia, and Mali with trial oversight by ethics committees at institutions such as London School of Hygiene & Tropical Medicine and University of Oxford. Safety and immunogenicity endpoints were compared to licensed polysaccharide vaccines from manufacturers like GlaxoSmithKline. Data monitored adverse events by surveillance networks coordinated with WHO and Centers for Disease Control and Prevention, demonstrating favorable safety profiles consistent with other conjugate vaccines used in programs run by Gavi, the Vaccine Alliance and observed in mass campaigns overseen by UNICEF. Post-licensure pharmacovigilance involved national drug regulatory authorities and collaborations with research centers such as Centre Muraz and Makerere University.
Mass vaccination campaigns targeted persons aged 1–29 years across countries including Burkina Faso, Chad, Niger, Mali, Nigeria, and Sudan, coordinated by ministries of health, WHO, UNICEF, and Médecins Sans Frontières. Campaign logistics drew on cold-chain experience from programs by PEPFAR and immunization initiatives supported by Gavi, the Vaccine Alliance. Strategies included door-to-door mobilization similar to campaigns mounted by Rotary International for polio eradication and community engagement models used by CARE International and Save the Children. Surveillance integration leveraged sentinel sites established by Institut Pasteur and laboratory networks including the Meningitis Research Foundation.
Following introduction, countries reported dramatic reductions in serogroup A meningitis incidence and elimination of large epidemics in many parts of the Meningitis Belt, as documented by World Health Organization surveillance reports and studies published with collaborators from London School of Hygiene & Tropical Medicine, Johns Hopkins University, and University of Oxford. Herd immunity effects mirrored earlier successes seen with Haemophilus influenzae type b and Streptococcus pneumoniae conjugate vaccines. Ongoing genomic surveillance by institutions such as Institut Pasteur and Africa Centres for Disease Control and Prevention monitored shifts in circulating Neisseria meningitidis lineages, while modeling studies from Imperial College London and Karolinska Institutet assessed long-term impact and serogroup replacement risks.
Manufacturing was scaled by the Serum Institute of India Private Limited with technology transfer supported by PATH and funding from the Bill & Melinda Gates Foundation. Distribution relied on logistics partners including UNICEF and freight coordination with World Health Organization procurement frameworks; financing mechanisms included support from Gavi, the Vaccine Alliance. Cost-effectiveness analyses by WHO and academic partners such as Harvard T.H. Chan School of Public Health evaluated program affordability relative to epidemic response spending documented by national ministries of finance and global donors.
Policy decisions for introduction were guided by recommendations from the World Health Organization Strategic Advisory Group of Experts on Immunization and implementation frameworks endorsed by Gavi, the Vaccine Alliance and donors including the Bill & Melinda Gates Foundation. Partnerships encompassed research institutions like London School of Hygiene & Tropical Medicine, delivery agencies such as UNICEF and Médecins Sans Frontières, and national ministries of health from countries across the Sahel and West Africa. Continued funding and policy attention have been coordinated with regional bodies including the African Union and Africa Centres for Disease Control and Prevention to sustain surveillance, booster strategies, and integration with routine immunization programs supported by multilateral and bilateral agencies.